Jeffries said Avivax will continue to rise thanks to positive data in the treatment of ulcerative colitis. Analyst Faisal Khurshid upgraded the French biotech company’s stock from hold to buy. He also raised his price target on the stock to $158 from $108, implying an 18% upside from Tuesday’s closing price. The upgrade came a day after new data on Avivax’s obefazimod showed that the aggressiveness of patients taking the drug was consistent with normal levels in patients with ulcerative colitis. Avivax added that more than a third of patients who initially did not respond to treatment achieved remission after about 10 months. Avivax’s U.S.-listed shares soared 39% on Tuesday, hitting their highest since July 23, 2025. ABVX YTD Mountain ABVX year-to-date data “adequately addresses the significant overhang facing the stock,” Khurshid wrote. “Management has done a good job of addressing investors’ concerns. …Moreover, the efficacy profile strengthens as more data is added. There are still risks to the funding runway, catalytic pathway, and the commercial need for a potential standalone launch. But ultimately, good data should yield value.” Earlier this month, the same analyst downgraded the company’s stock, citing that initial trial data “included cancer cases with no (at the time) clear explanation.” Now with more clarity, he is once again bullish on the stock. Avivax’s stock price rose more than 1% following the rating upgrade. Most analysts covering Avivax are bullish, with 10 out of 12 rating the company a “buy” or “strong buy,” according to LSEG.
